GemCap Provides $12.8MM Total Funding for Factoring Facilities
2022年8月26日 · GemCap, a lending firm that provides senior-secured, commercial asset-based loans and accounts receivable, funded $12.8 million in revolver and term loans to aerospace …
GemCap Implements FGI T.R.U.S.T. for Risk Mitigation
FGI Worldwide LLC announced GemCap, Texas-based provider of revolvers, term loans and factoring facilities for small and medium-sized businesses across the United States and …
四药化疗强度太大？这类胰腺癌术后辅助用吉西他滨 + 卡培他滨就 …
2024年12月25日 · ESPAC-4 是一项 III 期、双臂、开放标签、多中心、随机临床试验，研究目的是比较吉西他滨单药化疗 vs.吉西他滨联合卡培他滨（GemCap）在胰腺导管腺癌患者术后辅助 …
Gemcitabine Plus Capecitabine Compared With Gemcitabine …
2007年6月1日 · This phase III trial compared the efficacy and safety of gemcitabine (Gem) plus capecitabine (GemCap) versus single-agent Gem in advanced/metastatic pancreatic cancer.
FA Gem Capsule: Buy strip of 10.0 capsules at best price in India - 1mg
FA Gem Capsule is a dietary supplement, prescribed for iron deficiencies and anaemia. It is effective in treating niacin deficiency, vitamin B6 and vitamin C deficiency.
Gemcitabine and capecitabine (GemCap) | Cancer Research UK
It is a treatment for pancreatic cancer. How does GemCap work? These chemotherapy drugs destroy quickly dividing cells, such as cancer cells. How do you have GemCap? You have …
<br>吉西他滨-卡培他滨联合治疗胰腺癌的疗效和安全性：随机对 …
Recent randomized controlled trials revealed the combination of gemcitabine and capecitabine (GemCap) regime shows promising efficacy in pancreatic cancer patients. Here, we conducted …
<br>吉西他滨辅助治疗与吉西他滨联合卡培他滨治疗胰腺导管腺癌 …
3 期 ESPAC-4 试验表明，在欧洲，吉西他滨联合卡培他滨 (GemCap) 比吉西他滨 (Gem) 显着改善了总生存期 (OS)。 我们对亚洲人群中的 GemCap与Gem 进行了回顾性疗效和安全性评估。
辅助吉西他滨 (GEM) 与吉西他滨加卡培他滨 (GEMCAP) 在切除的 …
结果：分别有 161 名患者 (55.1%) 和 131 名患者 (44.8%) 使用了辅助 GEM 和 GEMCAP。 与 GEMCAP 组相比，GEM 组患者的年龄显着增加（中位数 66 岁 vs 63 岁，p = 0.025）；否 …
Efficacy and safety of gemcitabine-capecitabine combination
2021年12月3日 · Background: Recent randomized controlled trials revealed the combination of gemcitabine and capecitabine (GemCap) regime shows promising efficacy in pancreatic …